发明名称 FUSION PROTEINS FOR USE AS IMMUNOGENIC ENHANCERS FOR INDUCING ANTIGEN-SPECIFIC T CELL RESPONSES
摘要 A vaccine composition comprising a fusion protein for inducing enhanced pathogen antigen-specific T cell responses is disclosed. The fusion protein comprises: (a) an antigen-presenting cell (APC)-binding domain or a CD91 receptor-binding domain, located at the N-terminus of the fusion protein; (b) a translocation peptide of 34-112 amino acid residues in length, comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 4, 2, 3, or 6, located at the C-terminus of the APC-binding domain or the CD91 receptor-binding domain; and (c) an antigen of a pathogen, located at the C-terminus of the translocation peptide; (d) a nuclear export signal, comprising the amino acid sequence of SEQ ID NO: 13; and (e) an endoplasmic reticulum retention sequence, located at the C-terminus of the fusion protein.
申请公布号 WO2014089036(A1) 申请公布日期 2014.06.12
申请号 WO2013US72804 申请日期 2013.12.03
申请人 THEVAX GENETICS VACCINE CO., LTD.;HEALTHBANKS BIOTECH USA INC. 发明人 CHOU, WEI-I;WU, CHIA-MAO;WU, JIUN-MING;CHANG, HSIU-KANG
分类号 A61K39/104 主分类号 A61K39/104
代理机构 代理人
主权项
地址